- Home
- IBIO vs MYNZ Comparison
IBIO vs MYNZ Comparison
Compare IBIO & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- MYNZ
- Stock Information
- Founded
- IBIO 2008
- MYNZ 2021
- Country
- IBIO United States
- MYNZ Germany
- Employees
- IBIO N/A
- MYNZ N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- MYNZ Health Care
- Exchange
- IBIO Nasdaq
- MYNZ Nasdaq
- Market Cap
- IBIO 9.3M
- MYNZ 8.0M
- IPO Year
- IBIO N/A
- MYNZ 2021
- Fundamental
- Price
- IBIO $0.98
- MYNZ $2.08
- Analyst Decision
- IBIO Strong Buy
- MYNZ Buy
- Analyst Count
- IBIO 3
- MYNZ 2
- Target Price
- IBIO $4.87
- MYNZ $14.00
- AVG Volume (30 Days)
- IBIO 455.0K
- MYNZ 93.5K
- Earning Date
- IBIO 05-02-2025
- MYNZ 06-17-2025
- Dividend Yield
- IBIO N/A
- MYNZ N/A
- EPS Growth
- IBIO N/A
- MYNZ N/A
- EPS
- IBIO N/A
- MYNZ N/A
- Revenue
- IBIO $375,000.00
- MYNZ $893,991.00
- Revenue This Year
- IBIO $36.00
- MYNZ $26.06
- Revenue Next Year
- IBIO N/A
- MYNZ $4.97
- P/E Ratio
- IBIO N/A
- MYNZ N/A
- Revenue Growth
- IBIO 650.00
- MYNZ N/A
- 52 Week Low
- IBIO $0.64
- MYNZ $1.92
- 52 Week High
- IBIO $6.89
- MYNZ $34.00
- Technical
- Relative Strength Index (RSI)
- IBIO 48.45
- MYNZ 38.07
- Support Level
- IBIO $0.75
- MYNZ $1.93
- Resistance Level
- IBIO $1.03
- MYNZ $2.10
- Average True Range (ATR)
- IBIO 0.08
- MYNZ 0.16
- MACD
- IBIO 0.08
- MYNZ 0.04
- Stochastic Oscillator
- IBIO 75.74
- MYNZ 30.39
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.